Investor Notice: Robbins LLP Informs Investors of the Boston Scientific Corporation Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025 and February 3, 2026. Boston Scientific is a global company that develops, manufactures, and markets medical devices used across various specialties.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at [phone].

The Allegations: Robbins LLP is Investigating Allegations that Boston Scientific Corporation (BSX) Misled Investors Regarding Projected Revenue

According to the complaint, during the class period, defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. In truth, Boston Scientific’s ambition of continuing “to grow our share in the overall EP market” to maintain a growth trajectory at “2x the market” had fallen short of reality; the Company had begun to experience new competition entrants that were sapping Boston Scientific’s U.S. Electrophysiology market share and thus limiting the Company’s growth potential.

Plaintiff alleges that on February 4, 2026, Boston Scientific published a press release announcing fourth quarter and full year 2025 results, including a pertinent disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management’s previous claims of a “growing” EP business and assertions they “have a very good understanding of what competition we will face and in what time frame.” On this news, the price of Boston Scientific’s common stock declined over 17%, from a closing market price of $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026.

What Now: You may be eligible to participate in the class action against Boston Scientific Corporation. Shareholders who wish to serve as lead plaintiff for the class should contact Robbins LLP. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Boston Scientific Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.